| 000 | 01714 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517214640.0 | ||
| 264 | 0 | _c20181004 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a2352-3026 | ||
| 024 | 7 |
_a10.1016/S2352-3026(18)30054-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShen, Qiu-Dan | |
| 245 | 0 | 0 |
_aGemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. _h[electronic resource] |
| 260 |
_bThe Lancet. Haematology _cJun 2018 |
||
| 300 |
_ae261-e269 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aAntigens, CD20 |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganoplatinum Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aOxaliplatin |
| 650 | 0 | 4 |
_aRituximab _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aZhu, Hua-Yuan | |
| 700 | 1 | _aWang, Li | |
| 700 | 1 | _aFan, Lei | |
| 700 | 1 | _aLiang, Jin-Hua | |
| 700 | 1 | _aCao, Lei | |
| 700 | 1 | _aWu, Wei | |
| 700 | 1 | _aXia, Yi | |
| 700 | 1 | _aLi, Jian-Yong | |
| 700 | 1 | _aXu, Wei | |
| 773 | 0 |
_tThe Lancet. Haematology _gvol. 5 _gno. 6 _gp. e261-e269 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S2352-3026(18)30054-1 _zAvailable from publisher's website |
| 999 |
_c28382431 _d28382431 |
||